THRIVE-c score predicts clinical outcomes in Chinese patients after thrombolysis

Brain Behav. 2018 Jan 30;8(2):e00927. doi: 10.1002/brb3.927. eCollection 2018 Feb.

Abstract

Objectives: Total Health Risks in Vascular Events-calculation score (THRIVE-c) is an easy use and patient-specific outcome predictive score by computing the logistic equation with patients' continuous variables. We validated its performance in Chinese ischemic stroke patients receiving intravenous thrombolysis (IVT) therapy.

Materials and methods: We used data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) registry to validate the THRIVE-c score in patients receiving IVT therapy. We evaluated the score performance using area under the receiver operating characteristic curve (AUC). Receiver operator characteristic curve (ROC) was used to compare THRIVE-c score performance with other scores in predicting clinical outcome and symptomatic intracranial hemorrhage (SICH). Calibration was assessed by Pearson correlation coefficient and Hosmer-Lemeshow test.

Results: Among the 1,128 patients receiving IVT therapy included in this study, AUC of the THRIVE-c score for 3-month SICH, poor functional outcome, and mortality rate was 0.70 (95% CI: 0.63-0.76), 0.75 (95% CI: 0.73-0.78) and 0.81 (95% CI: 0.77-0.85), respectively. The increased THRIVE-c score was associated with higher risk of developing SICH, poor functional outcome, or mortality in patients with acute ischemic stroke at 3 months after thrombolysis. The performance of the THRIVE-c score was similar to or superior to other predictive scores (THRIVE score, SEDAN score, DRAGON score, HIAT2 score).

Conclusions: The THRIVE-c score reliably predicts the risks of 3-month SICH, poor functional outcome, and mortality after IVT therapy in Chinese patients with ischemic stroke.

Keywords: THRIVE‐c score; ischemic; prognosis; stroke; thrombolysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • China
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Intracranial Hemorrhages / prevention & control*
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • ROC Curve
  • Registries
  • Risk
  • Stroke / drug therapy*
  • Thrombolytic Therapy / methods*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents